Quantcast

Latest Cholangiocarcinoma Stories

2014-07-09 11:33:39

The Mount Sinai Hospital / Mount Sinai School of Medicine Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature. A team led by the Icahn School of Medicine at Mount Sinai and Harvard Medical School has discovered a link between the presence of two mutant proteins IDH1 and IDH2 and cancer. Past studies have found IDH...

2014-06-17 04:21:42

Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. announced today that the Company has initiated a randomized Phase 1b/2 Trial of CX-4945 in combination with gemcitabine and cisplatin for the frontline treatment of patients with bile duct cancers (cholangiocarcinoma). This Proof-of-Concept trial will study the use of CX-4945, a small molecule CK2 inhibitor, to suppress...

2014-04-09 23:29:35

Cancers of the liver are increasing in incidence faster than any other cancer in the U.S. and other western countries, and are a leading cause of cancer death worldwide. CanLiv - The Hepatobiliary Cancers Foundation will bring together researchers, cancer doctors, patient advocates, and industry partners to collaboratively develop better treatment for liver cancer patients at its 4th Annual Research Symposium, May 9, 2014 at ASCO Conference Center in Alexandria, VA. Alexandria, VA...

2014-03-26 08:28:35

Supplemental approval will expand PDT with Photofrin® treatments in specific lung and esophageal cancers TORONTO AND BANNOCKBURN, IL, March 26, 2014 /PRNewswire/ - Concordia Healthcare Corp. (Concordia or the Company) (TSX:CXR) (OTCQX: CHEHF) announced today that its subsidiary Pinnacle Biologics, Inc. (Pinnacle), a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental...

2014-01-13 08:27:08

Agreement represents continued movement forward in the development of a potential new treatment for rare cancers TORONTO and BANNOCKBURN, Ill., Jan. 13, 2014 /PRNewswire/ -- Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"), a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with the U.S. Food and Drug Administration (the "FDA") under a special protocol...

2013-11-04 10:40:59

A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer. The team, led by Professors Teh Bin Tean, Patrick Tan, Steve Rozen, Irinel Popescu and Vajaraphongsa Bhudhisawasdi, used advanced DNA sequencing...

2013-10-09 12:49:29

Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA. "Pancreatic cancer is a disease with a poor prognosis, mainly because of the inability to detect the tumor at an early stage, its high potential for early dissemination, and its relatively poor sensitivity...

2013-04-26 10:38:19

New data from two clinical trials presented today at the International Liver Congress 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests. HCC is common throughout the world and most often develops as a late complication of chronic viral hepatitis or cirrhosis of any cause. The overall survival rate of HCC is poor and so screening for HCC offers the best hope for early detection,...

2012-06-27 17:31:18

Comprehensive strategy includes more accurate CT scan analysis, complex surgical technique Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients. Pancreatic adenocarcinoma is one of the most devastating forms of pancreatic cancer with survival rates of only 5 percent at five years. Surgical removal...


Latest Cholangiocarcinoma Reference Libraries

Chinese Liver Fluke, Clonorchis sinensis
2014-01-12 00:00:00

The Chinese liver fluke (Clonorchis sinensis) is a species of parasitic worm that is classified within the Platyhelminthes phylum. It can be found in Southeast Asia, Taiwan, Japan, and China and is present in nearly 30,000,000 humans today. It is thought to be one of the world’s most pervading parasites. The Chinese liver fluke requires two intermediate, or secondary, hosts and one definitive, or main, host to successfully complete its lifecycle. The first intermediate host is typically...

More Articles (1 articles) »
Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related